Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
By Oliver Schmidt
HMGB1 is a key mediator in the immune response to SARS-CoV-2, and increased levels can be an important indicator for COVID-19 understanding and its prognosis. In this final piece in our series, we look at the performance of Tecan’s...
By Oliver Schmidt
In the first article in this series, we looked at how HMGB1 has taken an increasingly important position as a key mediator in the immune response, playing a major role in many diseases, from cancer to coronavirus. There is now...
By Oliver Schmidt
In the first article in this series, we looked at how HMGB1 has taken an increasingly important position as a key mediator in the immune response and as such plays a major role in a large number of diseases – from sepsis to cancer....
By Oliver Schmidt
As a nuclear protein present in most cell types, HMGB1 (high mobility group box 1) is a key mediator of the immune system in health and disease. Interest in HMGB1 has increased dramatically as the protein has been shown to be...
By Dr Christian Oberdanner
Last night you were up until midnight tending to your live-cell experiment. This morning you woke up with great expectations, only to find that your cells are sick and the entire experiment must be repeated. Sound...
By Dr. Christian Oberdanner.
Cell-based assays are a core research tool, offering an informative and cost-effective counterpart to in vitro and animal tests. Where destructive methods involving cell lysis once predominated, live cell assays are now...
By Siegfried Sasshofer
Imagine life science research without cell-based assays. Or without cultured cells of all types to power those assays. Healthy, high-quality cells at the right point of confluence are vital for proliferation, kinetics,...
By Rick Luedke You may be convinced that your academic research laboratory is humming along just fine and cannot benefit from, take the time to consider, and perhaps most of all, afford adding automation to your workflow.
By Dr Christian Oberdanner
Achieving reproducibility in a cell-based fluorescence assay can be a real challenge. For example, you might run a very basic experiment to determine the optimal concentration of cell media supplements for your primary...
By Kevin Moore
How can we improve upon the completely artificial situation that we have today for screening drugs? We spoke to Dr. Christopher Millan, Co-Founder and CTO of the up-and-coming company, CellSpring. Based in Zürich, Christopher Millan...
By Kevin Moore
With today's demands of throughput and flexibility, how can you perform screening better? We spoke to Dr. Bernhard Ellinger, Principal Scientist at the Fraunhofer Institute for Molecular Biology and Applied Ecology. Dr. Ellinger is...
By Severin Heynen
With multiple tests to perform on a tiny volume, samples are getting more precious. And as Next Generation Sequencing pushes the envelope on cost and throughput, scientists are looking for ways of reducing reagent volumes without...
By Michael Fejtl
“When you can measure what you are speaking about, and express it in numbers, you know something about it.” Lord Kelvin knew that. To be confident in your results, to quickly move your studies forward, and to be the first to publish...
By Michael Fejtl
When it comes to drug development, the challenge is always to create as much in-vivo relevant data as possible. The more relevant in-vivo data you can gather, the lower the risk of the drug not passing a clinical trial.
By Siegfried Sasshofer
What are the benefits of the new Spark® 20M when it comes to accelerating the drug discovery process? This presentation from SLAS2016 goes beyond discussing typical microplate readers and washers to covering processes for...